Close

Welcome back to Stockhouse
Member Sign In

Email or Username:
Password:
Close

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

Theratechnologies Inc T.TH

Sector: Healthcare | Sub-Sector: Biotechnology
Alternate Symbol(s):  THERF

Theratechnologies Inc is a pharmaceutical company addressing unmet medical needs in metabolic disorders. EGRIFTA is its registered trademark in the USA and it is used to commercialize its first product using its internally developed compound, tesamorelin.
Price: $0.77 | Change: +$0.03 | %Change: +4.05%
Volume: 109,693 | Day High/Low: N/A/N/A | 52 Week High/Low: 0.83/0.325
View modes: 
0 stars

RE:Long term safety studies

The observational study is supposed to last 15 years in total and the company estimates in the annual report that the annual cost will be $2.6 million. The retinopathy study is expected to cost $20...read more
0 stars

Long term safety studies

I own a rather large number of shares and feel that the upside is tremendous when looking at potential markets and cost structure, The only thing preventing me from increasing my position is the risks...read more
0 stars

RE:RE:RE:RE:Up 36% on the week and still massively undervalued

I think we agree that the amortization of the Payment to Serono is not significant Undervalued by a lot if they are able to get serious sales traction in the next few quarters  rate and reply
0 stars

RE:RE:RE:RE:Up 36% on the week and still massively undervalued

Royaties to Serono kick in in January 2016 and are likely to end about 4-5 years later after a capped dollar amount is reached. They scale up as revenues increase, but the company has not disclosed...read more
0 stars

RE:RE:RE:Up 36% on the week and still massively undervalued

I doubt that EBITDA will be that much different from net earnings. But either way, we all seem to agree thay TH is still substantially undervalued. And if they do get 2600 patients you'd be looking at...read more
0 stars

RE:RE:RE:Up 36% on the week and still massively undervalued

The only difference IMO between EBITDA and EARNINGS until the tax losses carry forward have been utilized will be the amortization of the payments made to Serono for re acquiring the rights to US I...read more
0 stars

RE:RE:Up 36% on the week and still massively undervalued

Remember, that is EBITDA, not earnings. But yes, those numbers are still very exciting and what the company is guiding the market to believe is likely if the sales are achieved. Now, the corporate...read more
0 stars

RE:RE:RE:Up 36% on the week and still massively undervalued

No one knows the answer to this, of course, but it is a reasonable bet that it is higher than the 1,300 or so Serono peaked out at. I would not be surprised if the company could double that number...read more
0 stars

RE:RE:Up 36% on the week and still massively undervalued

Further price hikes will come each year, but massive ones are no longer likely. While the company needs to make a profit and the large price hikes over the last year year insure that, I don't expect...read more
0 stars

RE:RE:Up 36% on the week and still massively undervalued

using the company s presentation any patient over 1400 adds almost 36 000 cad dollrs to the bottom line ...I wonder what is- the attainable number of patients? 3000 ? 4000? 5000?  rate and reply
0 stars

RE:Up 36% on the week and still massively undervalued

Up 36% for the week but still down almost 90% from when Egrifta was launched. And when I run the numbers for 1300 patients I get from the current presentation : @ 1200 = US$15.9 million @ 1400 = US$21...read more
0 stars

RE:Up 36% on the week and still massively undervalued

"The 42% hike in the US price of Egrifta..." Once TH has penetrated the market and assured itself profitability what is preventing one more significant price hike if there are no other options for...read more
0 stars

Up 36% on the week and still massively undervalued

If you run the numbers the company ahs provided, it will be hard for TH not to earn $0.20 per share in 2016. And this only assumes that it manages to get back to the same level of sales as Serono...read more
0 stars

RE:RE:RE:canacord

A bit disturbing that the largest seller on the day of the upgrade by Canacord is a client of theirs! Just a coincidence I hope!!  rate and reply
0 stars

RE:RE:canacord

Not sure. But one or more of their clients have been selling quite a bit over the last few weeks.  rate and reply
0 stars

RE:canacord

How many shares did Canacord sell today?  rate and reply
0 stars

RE:canacord

Expect the target price to be raised next quarter IF they execute  rate and reply
0 stars

canacord

Raise TH from HOLD to BUY. Target $1.50  rate and reply
0 stars

RE:RE:RE:RE:RE:Great news this morning

This is very nice news but if it somehow takes your eye off the fact the company just upped its base case earnings potential by 70%+ yesterday, then you are missing the proverbial "forest for the...read more
0 stars

RE:RE:RE:RE:Great news this morning

Spain, Greece, Ireland? Any sales they get from Europe this year would be completely gravy and completely unexpected.  We'll see how it goes...  rate and reply